Comparison of R-ketamine and rapastinel antidepressant effects in the social defeat stress model of depression

Psychopharmacology

Volumn 233, Issue 19-20, 2016, Pages 3647-3657

  Yang, Bangkun ^a,b   Zhang, Ji chun ^a   Han, Mei ^a   Yao, Wei ^a   Yang, Chun ^a   Ren, Qian ^a   Ma, Min ^a   Chen, Qian Xue ^b   Hashimoto, Kenji ^a  

^a CHIBA UNIVERSITY   (Japan)

^b RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

Author keywords

Antidepressant; Brain derived neurotrophic factor; R ketamine; Rapastinel; Synaptogenesis

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; GLUTAMATE RECEPTOR 1; KETAMINE; POSTSYNAPTIC DENSITY PROTEIN 95; RAPASTINEL; AMINO ACID RECEPTOR BLOCKING AGENT; AMPA RECEPTOR; ANTIDEPRESSANT AGENT; DISKS LARGE HOMOLOG 4; DLG4 PROTEIN, MOUSE; GLUTAMATE RECEPTOR IONOTROPIC, AMPA 1; GLYX-13 PEPTIDE; OLIGOPEPTIDE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDEPRESSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DENTATE GYRUS; DEPRESSION; DRUG EFFECT; FORCED SWIM TEST; HIPPOCAMPAL CA3 REGION; LOCOMOTION; MALE; MOUSE; NONHUMAN; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SUCROSE PREFERENCE TEST; TAIL SUSPENSION TEST; ANIMAL; BRAIN; COMPARATIVE STUDY; DISEASE MODEL; DRUG EFFECTS; HIPPOCAMPUS; IMMOBILIZATION; MENTAL STRESS; METABOLISM; SWIMMING;

ANIMALS; ANTIDEPRESSIVE AGENTS; BRAIN; BRAIN-DERIVED NEUROTROPHIC FACTOR; CA3 REGION, HIPPOCAMPAL; DENTATE GYRUS; DEPRESSION; DISEASE MODELS, ANIMAL; DISKS LARGE HOMOLOG 4 PROTEIN; EXCITATORY AMINO ACID ANTAGONISTS; HINDLIMB SUSPENSION; HIPPOCAMPUS; KETAMINE; MALE; MICE; NUCLEUS ACCUMBENS; OLIGOPEPTIDES; PREFRONTAL CORTEX; RECEPTOR, TRKB; RECEPTORS, AMPA; STRESS, PSYCHOLOGICAL; SWIMMING;

EID: 84982815546     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-016-4399-2     Document Type: Article

References (43)

1. Aan Het Rot M, Zarate CA Jr, Charney DS, Mathew SJ (2012) Ketamine for depression: where do we go from here? Biol Psychiatry 72:537–547
2. Autry AE, Adachi M, Nosyreva E, Na ES, Los MF, Cheng PF, Kavalali ET, Monteggia LM (2011) NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 475:91–95
3. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, Krystal JH (2000) Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 47:351–354
4. Berton O, McClung CA, Dileone RJ, Krishnan V, Renthal W, Russo SJ, Graham D, Tsankova NM, Bolanos CA, Rios M, Monteggia LM, Self DW, Nestler EJ (2006) Essential role of BDNF in the mesolimbic dopamine pathway in social defeat stress. Science 311:864–868
5. Burgdorf J, Zhang XL, Nicholson KL, Balster RL, Leander JD, Stanton PK, Gross AL, Kroes RA, Moskal JR (2013) GLYX-13, a NMDA receptor glycine-site functional partial agonist, induces antidepressant-like effects without ketamine-like side effects. Neuropsychopharmacology 38:729–742
6. Chaki S, Fukumoto K (2015) Potential of glutamate-based drug discovery for next generation antidepressants. Pharmaceuticals (Basel) 8:590–606
7. Diazgranados N, Ibrahim L, Brutsche NE, Newberg A, Kronstein P, Khalife S, Kammerer WA, Quezado Z, Luckenbaugh DA, Salvadore G, Machado-Vieira R, Manji HK, Zarate CA Jr (2010) A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry 67:793–802
8. Domino EF (2010) Taming the ketamine tiger. 1965. Anesthesiology 113:678–684
9. Duman RS, Aghajanian GK (2012) Synaptic dysfunction in depression: potential therapeutic targets. Science 338:68–72
10. Golden SA, Covington HE III, Berton O, Russo SJ (2011) A standard protocol for repeated social defeat stress in mice. Nat Protoc 6:1183–1191
11. Hashimoto K (2009) Emerging role of glutamate in the pathophysiology of major depressive disorder. Brain Res Rev 61:105–123
12. Hashimoto K (2014) The R-stereoisomer of ketamine as an alternative for ketamine for treatment-resistant major depression. Clin Psychopharmacol Neurosci 12:72–73
13. Hashimoto K (2015) Inflammatory biomarkers as differential predictors of antidepressant response. Int J Mol Sci 16:7796–7801
14. Hashimoto K (2016a) R-ketamine: a rapid-onset and sustained antidepressant without risk of brain toxicity. Psychol Med 46:2449–2451
15. Hashimoto K (2016b) Detrimental side effects of repeated ketamine infusions in brain. Am J Psychiatry. doi:10.1176/appi.ajp.2016.16040411
16. Hashimoto K, Malchow B, Falkai P, Schmitt A (2013) Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders. Eur Arch Psychiatry Clin Neurosci 263:367–377
17. Krystal JH, Sanacora G, Duman RS (2013) Rapid-acting glutamergic antidepressants: the path to ketamine and beyond. Biol Psychiatry 73:1133–1141
18. Lepack AE, Fuchikami M, Dwyer JM, Banasr M, Duman RS (2014) BDNF release is required for the behavioral actions of ketamine. Int J Neuropsychopharmacol 18:pyu033
19. Li N, Lee B, Liu RJ, Banasr M, Dwyer JM, Iwata M, Li XY, Aghajanian G, Duman RS (2010) mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 329:959–964
20. Lodge D, Mercier MS (2015) Ketamine and phencyclidine: the good, the bad and the unexpected. Br J Pharmacol 172:4254–4276
21. Lu Y, Wang C, Xue Z, Li C, Zhang J, Zhao X, Liu A, Wang Q, Zhou W (2014) PI3K/AKT/mTOR signaling-mediated neuropeptide VGF in the hippocampus of mice is involved in the rapid onset antidepressant-like effects of GLYX-13. Int J Neuropsychopharmacol 18:pyu110
22. Ma XC, Dang YH, Jia M, Ma R, Wang F, Wu J, Gao CG, Hashimoto K (2013) Long-lasting antidepressant action of ketamine, but not glycogen synthase kinase-3 inhibitor SB216763, in the chronic mild stress model of mice. PLoS One 8:e56053
23. Monteggia LM, Zarate CA Jr (2015) Antidepressant actions of ketamine: from molecular mechanisms to clinical practice. Curr Opin Neurobiol 30:139–143
24. Moskal JR, Burch R, Burgdorf JS, Kroes RA, Stanton PK, Disterhoft JF, Leander JD (2014) GLYX-13, an NMDA receptor glycine site functional partial agonist enhances cognition and produces antidepressant effects without the psychotomimetic side effects of NMDA receptor antagonists. Expert Opin Investig Drugs 23:243–254
25. Moskal JR, Burgdorf JS, Stanton PK, Kroes RA, Disterhoft JF, Burch RM, Amin Khan M (2016) The development of rapastinel (formerly GLYX-13); a rapid acting and long lasting antidepressant. Curr Neuropharmacol. doi:10.2174/1570159X14666160321122703
26. Nestler EJ, Carlezon WA Jr (2006) The mesolimbic dopamine reward circuit in depression. Biol Psychiatry 59:1151–1159
27. Ohgi Y, Futamura T, Hashimoto K (2015) Glutamate signaling in synaptogenesis and NMDA receptors as potential therapeutic targets for psychiatric disorders. Curr Mol Med 15:206–221
28. Preskorn S, Macaluso M, Mehra DO, Zammit G, Moskal JR, Burch RM, GLYX-13 Clinical Study Group (2015) Randomized proof of concept trial of GLYX-13, an N-methyl-D-aspartate receptor glycine site partial agonist, in major depressive disorder nonresponsive to a previous antidepressant agent. J Psychiatr Pract 21:140–149
29. Ren Q, Ma M, Ishima T, Morisseau C, Yang J, Wagner KM, Zhang JC, Yang C, Yao W, Dong C, Han M, Hammock BD, Hashimoto K (2016) Gene deficiency and pharmacological inhibition of soluble epoxide hydrolase confers resilience to repeated social defeat stress. Proc Natl Acad Sci U S A 113:E1944–E1952
30. Ren Q, Ma M, Yang C, Zhang JC, Yao W, Hashimoto K (2015) BDNF-TrkB signaling in the nucleus accumbens shell of mice has key role in methamphetamine withdrawal symptoms. Transl Psychiatry 5:e666
31. Sanacora G, Schatzberg AF (2015) Ketamine: promising path or false prophecy in the development of novel therapeutics for mood disorders? Neuropsychopharmacology 40:259–267
32. Sato Y, Kobayashi E, Hakamata Y, Kobahashi M, Wainai T, Murayama T, Mishina M, Seo N (2004) Chronopharmacological studies of ketamine in normal and NMDA epsilon 1 receptor knockout mice. Bri J Anaesth 92:859–864
33. Shirayama Y, Yang C, Zhang JC, Ren Q, Yao W, Hashimoto K (2015) Alterations in brain-derived neurotrophic factor (BDNF) and its precursor proBDNF in the brain regions of a learned helplessness rat model and the antidepressant effects of a TrkB agonist and antagonist. Eur Neuropsychopharmacol 25:2449–2458
34. Singh JB, Fedgchin M, Daly E, Xi L, Melman C, De Bruecker G, Tadic A, Sienaert P, Wiegand F, Manji H, Drevets WC, Van Nueten L (2016) Intravenous esketamine in adult treatment-resistant depression: a double-blind, double-randomization, placebo-controlled study. Biol Psychiatry. doi:10.1016/j.biopsych.2015.10.018
35. Yang C, Hashimoto K (2014) Rapid antidepressant effects and abuse liability of ketamine. Psychopharmacology (Berl) 231:2041–2042
36. Yang C, Shirayama Y, Zhang JC, Ren Q, Hashimoto K (2015a) Regional differences in brain-derived neurotrophic factor levels and dendritic spine density confer resilience to inescapable stress. Int J Neuropsychopharmacol 18:pyu121
37. Yang C, Shirayama Y, Zhang JC, Ren Q, Yao W, Ma M, Dong C, Hashimoto K (2015b) R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects. Transl Psychiatry 5:e632
38. Yang C, Han M, Zhang JC, Ren Q, Hashimoto K (2016) Loss of parvalbumin-immunoreactivity in mouse brain regions after repeated intermittent administration of esketamine, but not R-ketamine. Psychiatry Res 239:281–283
39. Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, Manji HK (2006) A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 63:856–864
40. Zarate CA Jr, Brutsche NE, Ibrahim L, Franco-Chaves J, Diazgranados N, Cravchik A, Selter J, Marquardt CA, Liberty V, Luckenbaugh DA (2012) Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry 71:939–946
41. Zhang JC, Li SX, Hashimoto KJ (2014) R(−)-ketamine shows greater potency and longer lasting antidepressant effects than S(+)-ketamine. Pharmacol Biochem Behav 116:137–141
42. Zhang JC, Wu J, Fujita Y, Yao W, Ren Q, Yang C, Li SX, Shirayama Y, Hashimoto K (2015a) Antidepressant effects of TrkB ligands on depression-like behavior and dendritic changes in mice after inflammation. Int J Neuropsychopharmacol 18:pyu077
43. Zhang JC, Yao W, Dong C, Yang C, Ren Q, Ma M, Han M, Hashimoto K (2015b) Comparison of ketamine, 7,8-dihydroxyflavone, and ANA-12 antidepressant effects in the social defeat stress model of depression. Psychopharmacology (Berl) 232:4325–4335